Listenly

How does the adjuvant Matrix M enhance the effectiveness of the R21 vaccine in clinical trials?

Answered at 17:27 in Parasite, the Malaria (Tech & Science) Edition · 16 Minutes News by a16z

— questions searchable right now

How does the adjuvant Matrix M enhance the effectiveness of the R21 vaccine in clinical trials?

Adjuvants are immune-system boosters that enable smaller vaccine doses while still training the body to recognize a pathogen. Matrix M achieves this by generating a protective immune response, and has also proven effective in Novavax's COVID-19 vaccine development alongside GSK's shingles vaccine, which uses a chemically related adjuvant.

What is an adjuvant?

An adjuvant is a substance added to a vaccine that enhances the body's immune response. Rather than requiring a full dose of vaccine protein to train immunity, adjuvants allow vaccine developers to use smaller quantities while maintaining or even improving effectiveness—a critical advantage for manufacturing scale and distribution in resource-limited settings.

How Matrix M works in R21 trials

Matrix M is the specific adjuvant chosen for the R21 malaria vaccine, selected based on its track record and chemical properties. As detailed in the episode discussion of vaccine mechanics, phase two data confirmed that Matrix M generates protective immune responses sufficient to move forward into larger clinical trials.

The R21 vaccine achieved a 77 percent efficacy rate over 12 months in its phase 2B trial, which included 450 participants aged 5 to 17 months from Burkina Faso. This result represented a meaningful step toward the World Health Organization's target efficacy of 75 percent for future malaria vaccines.

Rajiv Venkayya on 16 Minutes News by a16zAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Adjuvants are immune-system boosters that enable smaller vaccine doses while still training the body to recognize a pathogen.

Rajiv Venkayya · Parasite, the Malaria (Tech & Science) Edition · 16 Minutes News by a16z · answer at 17:27

Key takeaways

  • Matrix M achieves this by generating a protective immune response, and has also proven effective in Novavax's COVID-19 vaccine development alongside GSK's shingles vaccine, which uses a chemically related adjuvant.
  • An adjuvant is a substance added to a vaccine that enhances the body's immune response.
  • Matrix M is the specific adjuvant chosen for the R21 malaria vaccine, selected based on its track record and chemical properties.
  • The R21 vaccine achieved a 77 percent efficacy rate over 12 months in its phase 2B trial, which included 450 participants aged 5 to 17 months from Burkina Faso.

The full answer · about 1 min

Adjuvants are immune-system boosters that enable smaller vaccine doses while still training the body to recognize a pathogen. Matrix M achieves this by generating a protective immune response, and has also proven effective in Novavax's COVID-19 vaccine development alongside GSK's shingles vaccine, which uses a chemically related adjuvant.

What is an adjuvant?

An adjuvant is a substance added to a vaccine that enhances the body's immune response. Rather than requiring a full dose of vaccine protein to train immunity, adjuvants allow vaccine developers to use smaller quantities while maintaining or even improving effectiveness—a critical advantage for manufacturing scale and distribution in resource-limited settings.

How Matrix M works in R21 trials

Matrix M is the specific adjuvant chosen for the R21 malaria vaccine, selected based on its track record and chemical properties. As detailed in the episode discussion of vaccine mechanics, phase two data confirmed that Matrix M generates protective immune responses sufficient to move forward into larger clinical trials.

The R21 vaccine achieved a 77 percent efficacy rate over 12 months in its phase 2B trial, which included 450 participants aged 5 to 17 months from Burkina Faso. This result represented a meaningful step toward the World Health Organization's target efficacy of 75 percent for future malaria vaccines.

More answers from this episode

 ·  All answers from 16 Minutes News by a16z →
—
—
0:00
0:00